|
|
Aditxt Inc (NASDAQ: ADTX) |
|
Price: $6.8500
$-0.11 
-1.580%
|
| Day's High:
| $7.6928
| Week Perf:
| -35.92 %
|
| Day's Low: |
$ 6.51 |
30 Day Perf: |
-68.58 % |
| Volume (M): |
364 |
52 Wk High: |
$ 1,362.50 |
| Volume (M$): |
$ 2,495 |
52 Wk Avg: |
$249.84 |
| Open: |
$6.68 |
52 Wk Low: |
$5.00 |
|
|
| Market Capitalization (Millions $) |
12 |
| Shares
Outstanding (Millions) |
2 |
| Employees |
23 |
| Revenues (TTM) (Millions $) |
0 |
| Net Income (TTM) (Millions $) |
-38 |
| Cash Flow (TTM) (Millions $) |
1 |
| Capital Exp. (TTM) (Millions $) |
0 |
Aditxt Inc
Aditxt Inc is a biotechnology company based in the United States. The company specializes in developing innovative technologies and solutions in the field of health diagnostics. Aditxt focuses on leveraging its Immune Monitoring BioSensor Platform to develop advanced diagnostics tests that can provide information about an individual's immune system health. Their aim is to improve disease detection and monitoring, medication efficacy, and personalized medicine. The company's technology combines bioinformatics, immunology, and data science to provide insights into an individual's immune system functioning and overall health. Aditxt Inc aims to revolutionize the healthcare industry through its cutting-edge diagnostics solutions.
Company Address: 737 N. Fifth Street Richmond 23219 VA
Company Phone Number: 870-1200 Stock Exchange / Ticker: NASDAQ ADTX
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Business Update
Published Mon, Jan 13 2025 4:20 PM UTC
Aditxt Sets Sights on IPO for Pearsanta: Implications for the Future of Early Cancer Detection In a significant move poised to reshape the landscape of early cancer detection, Aditxt, Inc. (NASDAQ: ADTX) has announced that its Board of Directors has unanimously approved a plan to position its subsidiary, Pearsanta, Inc., for an initial public offering (IPO) scheduled for 202...
|
| Business Update
Published Thu, Dec 12 2024 2:24 PM UTC
Aditxt?s Bold Leap: Adimune Completes Pivotal Preclinical Trials, Eyes First-in-Human Clinical Breakthrough In a noteworthy stride toward revolutionizing the field of immune modulation, Aditxt, Inc. (NASDAQ: ADTX) announced a landmark achievement through its subsidiary Adimune, Inc. Adimune has successfully concluded preclinical efficacy and safety studies for its groundbrea...
|
| Business Update
Published Mon, Nov 11 2024 4:03 AM UTC
Aditxt: Navigating the Equity Landscape Amidst Market Dynamics In the ever-evolving realm of biotechnology, staying abreast of financial manoeuvres is as crucial as the innovations that underpin the industry. Aditxt, Inc. (NASDAQ: ADTX), a firm dedicated to catalysing groundbreaking health solutions, recently reached out to its shareholders with key updates regarding its equ...
|
| Business Update
Published Sat, Nov 9 2024 3:47 AM UTC
Aditxt, Inc. Updates Shareholders on Strategic Financial Moves and Acquisition Efforts Amid a Reverse Stock Split MOUNTAIN VIEW, Calif. Aditxt, Inc. (NASDAQ: ADTX), a dynamic innovation platform devoted to accelerating promising health technologies, has released a significant update for its shareholders, shedding light on the recent utilization of its Equity Line of Cred...
|
| Business Update
Published Fri, Nov 8 2024 4:36 PM UTC
Aditxt s Strategic Moves: Equity Line Optimizations, Stock Consolidation, and Innovations in Cancer Detection MOUNTAIN VIEW, Calif. Aditxt, Inc. (NASDAQ: ADTX), an innovation-centric social platform, continues to solidify its foothold in the health innovations landscape by unveiling strategic updates concerning its financial and clinical pursuits. These moves underscore th...
|
| Per Share |
Current |
| Earnings (TTM) |
-98.9 $ |
| Revenues (TTM) |
0.26 $
|
| Cash Flow (TTM) |
0.75 $ |
| Cash |
0.05 $
|
| Book Value |
3.52 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-98.9 $
|
| Revenues (TTM) |
0.26 $ |
| Cash Flow (TTM) |
0.75 $ |
| Cash |
0.05 $
|
| Book Value |
3.52 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
